Cancer Imaging (Mar 2023)

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

  • Kyoichi Kaira,
  • Ou Yamaguchi,
  • Ichiro Naruse,
  • Yukihiro Umeda,
  • Takeshi Honda,
  • Satoshi Watanabe,
  • Kosuke Ichikawa,
  • Shin Yanagisawa,
  • Norimitsu Kasahara,
  • Tetsuya Higuchi,
  • Kosuke Hashimoto,
  • Yu Miura,
  • Ayako Shiono,
  • Atsuto Mouri,
  • Hisao Imai,
  • Kunihiko Iizuka,
  • Tamotsu Ishizuka,
  • Koichi Minato,
  • Satoshi Suda,
  • Hiroshi Kagamu,
  • Keita Mori,
  • Nobuhiko Seki,
  • Ichiei Kuji

DOI
https://doi.org/10.1186/s40644-023-00538-x
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Purpose To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 54 patients with advanced NSCLC who had 2-deoxy-2-[fluorine-18]-fluoro-D-glucose PET or CT at baseline, and 4 and 9 weeks after PD-1 blockade, were registered. Therapeutic response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), the immune-modified RECIST (irRECIST), the PET Response Criteria in Solid Tumors (PERCIST), the immune-modified PERCIST (iPERCIST), and the European Organization for Research and Treatment of Cancer (EORTC) criteria for dichotomous groups, such as responders vs. non-responders and controlled vs. uncontrolled diseases. Cohen’s κ was used to evaluate the concordance among the different criteria. Results The concordance between CT and PET response criteria was fair or slight for responders vs. non-responders, but the agreement between iPERCIST and irRECIST was moderate for controlled vs. uncontrolled diseases. The agreement between EORTC and PERCIST or iPERCIST in detecting responders was higher in the application of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) than in the standardized uptake value corrected for lean body mass (SUL)peak. To distinguish controlled from uncontrolled disease, RECIST, irRECIST, and PET criteria (PERCIST, iPERCIST, and EORTC) defined by MTV or TLG were found to be significant predictors of progression-free survival. To distinguish responders from non-responders, iPERCIST by SULpeak or EORTC by TLG were identified as significant indicators. The EORTC criteria using TLG for the detection of responders or uncontrolled diseases had a significantly higher predictive value for response assessment. Conclusions The EORTC criteria based on TLG for the early detection of responders and uncontrolled disease were effective as a response assessment at 4 weeks after the PD-1 blockade. When SULpeak was not used but MTV or TLG was, the agreement between EORTC and PERCIST or iPERCIST was almost perfect.

Keywords